Natural selection of tumor variants in the generation of "tumor escape" phenotypes

被引:824
作者
Khong, HT [1 ]
Restifo, NP [1 ]
机构
[1] Natl Canc Inst, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1038/ni1102-999
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The idea that tumors must "escape" from immune recognition contains the implicit assumption that tumors can be destroyed by immune responses either spontaneously or as the result of immunotherapeutic intervention. Simply put, there is no need for tumor escape without immunological pressure. Here, we review evidence supporting the immune escape hypothesis and critically explore the mechanisms that may allow such escape to occur. We discuss the idea that the central engine for generating immunoresistant tumor cell variants is the genomic instability and dysregulation that is characteristic of the transformed genome. "Natural selection" of heterogeneous tumor cells results in the survival and proliferation of variants that happen to possess genetic and epigenetic traits that facilitate their growth and immune evasion. Tumor escape variants are likely to emerge after treatment with increasingly effective immunotherapies.
引用
收藏
页码:999 / 1005
页数:7
相关论文
共 105 条
[1]   Altered MHC class I antigens in tumors [J].
Algarra, I ;
Collado, A ;
Garrido, F .
INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1997, 27 (02) :95-102
[2]  
Almand B, 2000, CLIN CANCER RES, V6, P1755
[3]   Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles [J].
Andreola, G ;
Rivoltini, L ;
Castelli, C ;
Huber, V ;
Perego, P ;
Deho, P ;
Squarcina, P ;
Accornero, P ;
Lozupone, F ;
Lugini, L ;
Stringaro, A ;
Molinari, A ;
Arancia, G ;
Gentile, M ;
Parmiani, G ;
Fais, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (10) :1303-1316
[4]   Do CD4+CD25+ immunoregulatory T cells hinder tumor immunotherapy? [J].
Antony, PA ;
Restifo, NP .
JOURNAL OF IMMUNOTHERAPY, 2002, 25 (03) :202-206
[5]  
Apte RS, 1997, INVEST OPHTH VIS SCI, V38, P1277
[6]   Gene transfer of Fas ligand induces tumor regression in vivo [J].
Arai, H ;
Gordon, D ;
Nabel, EG ;
Nabel, GJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (25) :13862-13867
[7]   Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA [J].
Bauer, Stefan ;
Groh, Veronika ;
Wu, Jun ;
Steinle, Alexander ;
Phillips, Joseph H. ;
Lanier, Lewis L. ;
Spies, Thomas .
JOURNAL OF IMMUNOLOGY, 2018, 200 (07) :2231-2233
[8]   High frequency of altered HLA class I phenotypes in invasive breast carcinomas [J].
Cabrera, T ;
Fernandez, MA ;
Sierra, A ;
Garrido, A ;
Herruzo, A ;
Escobedo, A ;
Fabra, A ;
Garrido, F .
HUMAN IMMUNOLOGY, 1996, 50 (02) :127-134
[9]   Death receptor ligands in tumors [J].
Cappello, P ;
Novelli, F ;
Forni, G ;
Giovarelli, M .
JOURNAL OF IMMUNOTHERAPY, 2002, 25 (01) :1-15
[10]   A new mechanism of NK cell cytotoxicity activation: The CD40-CD40 ligand interaction [J].
Carbone, E ;
Ruggiero, G ;
Terrazzano, G ;
Palomba, C ;
Manzo, C ;
Fontana, S ;
Spits, H ;
Karre, K ;
Zappacosta, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (12) :2053-2060